Key Highlights

  • Accuray's fiscal 2026 Revenue fell 12% to $401.9 million, with product revenue down 27% to $172.7 million, while service revenue rose 4% to $229.2 million.
  • iTonic Holdings reported about $523,000 of revenue for 2025, up from $448,000, while its net loss widened to about $5.1 million, and it faces an October 19, 2026 Nasdaq bid-price deadline.
  • Accuray ended fiscal 2026 with $40.6 million in cash and $147.9 million of total debt, after a TCW Asset Management financing that provided covenant relief through December 2027.
  • iTonic sold 100 million Class A shares at $0.20 each in April 2026 for about $20 million and has approved a 1-for-16 share consolidation set to take effect October 6, 2026.

Accuray (NASDAQ:ARAY) and iTonic Holdings (NASDAQ:ITOC) both make technology for radiation-based cancer treatment, yet they are about as far apart in scale as two Nasdaq-listed healthcare companies can be. Accuray reported roughly $400 million of annual revenue and sells large treatment systems to hospitals around the world. iTonic, based in Beijing, reported about half a million dollars of revenue for 2025 from brachytherapy planning software and supplies. That contrast shows how an investor's questions change with company size: for Accuray, the focus is orders, margins and debt; for iTonic, it is listing compliance, share structure and whether a very small Business can build something new.

Accuray (NASDAQ:ARAY): A Hospital Equipment Maker in Transition

Accuray develops external-beam radiation therapy systems, including the CyberKnife, TomoTherapy and Radixact platforms. Its business combines one-time product sales, which depend on hospital Capital budgets, with recurring service contracts, a mix that is central to its fiscal 2026 results, reported August 19 for the year ended June 30.

Revenue for fiscal 2026 fell 12% to $401.9 million. Product revenue dropped 27% to $172.7 million, while service revenue rose 4% to $229.2 million. The net loss for the year was $49.2 million, and adjusted EBITDA was $10.6 million. In the fourth quarter alone, revenue declined 21% to $100.9 million from $127.5 million a year earlier, but gross Margin improved to 34.8% from 30.6% and the net loss was a relatively small $1.9 million. Management attributed weaker product Demand in some regions, including China and the Middle East, to geopolitical developments and Tariff uncertainty.

Accuray ended June with $40.6 million in cash and cash equivalents and total Debt of $147.9 million. During the year it completed a financing with TCW Asset Management that it said improved Liquidity and provided covenant relief through December 2027. The company said its transformation plan delivered more than $20 million of cost and margin improvement, above its original $12 million target. It is not providing formal fiscal 2027 revenue or adjusted EBITDA guidance. Order Backlog stood at $312.5 million at June 30, with a fourth-quarter book-to-bill ratio of 0.9.

iTonic Holdings (NASDAQ:ITOC): A Micro-Cap Brachytherapy Specialist

iTonic Holdings operates through Beijing Feitian Zhaoye Technology and focuses on brachytherapy, in which small radioactive sources are placed inside or next to a tumor. Its proprietary treatment planning system helps physicians work out target Volume and dose, and the company also sells supplies such as seed implant needles and patient positioning devices. It completed its Nasdaq IPO in September 2024 and, as a foreign private issuer, reports on a semiannual basis.

iTonic's revenue for the year ended December 31, 2025 was about $523,000, up from about $448,000 in 2024, while its net loss widened to about $5.1 million from well under $1 million. In July 2026 the company described work on an AI-enabled, browser-based cloud treatment planning platform through Mili Medical, a Subsidiary in which it holds a 60% stake, saying internal testing and workflow validation were under way but that the platform had not been clinically validated or approved by regulators in China.

Capital structure changes have been dramatic. In April 2026, iTonic sold 100 million Class A shares at $0.20 each for gross proceeds of approximately $20 million, subject to a six-month lock-up. By September it reported 109,382,000 Class A and 7,668,000 Class B shares outstanding, indicating that the Placement accounts for the large majority of shares now in issue. Nasdaq gave the company until October 19, 2026 to meet the $1 minimum bid price rule, and shareholders approved a 1-for-16 share consolidation on September 9, 2026, slated to take effect October 6. In late August 2026, law firm announcements also publicized a securities class action involving the stock; those allegations have not been proven.

What Scale and Maturity Tell Investors

Accuray's challenges are those of an established manufacturer: shrinking equipment orders, tariffs, margin repair and a meaningful debt load. iTonic's are more basic: building a revenue base, proving a new software product and keeping its listing.

  • Orders and backlog: For Accuray, gross orders and book-to-bill indicate whether product revenue can stabilize.
  • Service share: Accuray's growing service revenue offers some recurring support while hardware sales fluctuate.
  • Listing status: For iTonic, the key near-term test is whether the consolidation restores bid-price compliance.
  • Use of proceeds: Investors in iTonic may want to track how the April placement funds are deployed relative to a very small operating base.

Using the Nasdaq Composite as a Benchmark

Both companies trade on Nasdaq, but the Nasdaq Composite is used here purely as a comparison benchmark, not as a claim about index membership. Measuring each stock against the Composite over identical periods helps separate stock-specific outcomes from general market direction.

The yardstick fits the two differently. Accuray's shares tend to respond to orders and guidance, and the Composite can highlight how its equipment cycle diverges from large-cap technology. iTonic's price, which traded near $0.33 in September 2026, can swing sharply, so its relative returns should be read alongside Volatility and share-count changes.

Risks

For Accuray, the main risks include continued weakness in product demand, exposure to tariffs and geopolitical conditions in key regions, a net loss for the year, roughly $148 million of debt, and the absence of formal guidance for fiscal 2027. Execution on its transformation plan and the contribution of its China joint venture also matter.

iTonic's risks are more existential: a revenue base of roughly half a million dollars, a 2025 net loss about ten times that figure, a Nasdaq bid-price deadline, a pending share consolidation, regulatory uncertainty around its AI platform in China and pending litigation. Its reliance on a single subsidiary in China adds jurisdictional and disclosure considerations.

A Shared Field, Little Else in Common

Accuray and iTonic share a field but little else. Accuray is a sizable equipment and service provider working through lower product sales and a refinancing, with service revenue as a steadier base. iTonic is a tiny brachytherapy software firm whose near-term story centers on listing compliance, a heavily expanded share count and an early-stage AI project. Measured against the Nasdaq Composite, each should be judged on the metrics that fit its stage.